Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Cvac in Ovarian Cancer Patients from CAN-003
NCT01617629Phase 2Completed
- Sponsor
- Immutep Limited
- Start
- Dec 2011
- Primary completion
- Apr 2014
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 2
01
Overview
A Phase 2 trial of CVac in epithelial ovarian cancer (EOC), sponsored by Immutep Limited. Started Dec 2011; status: completed.
02
Drugs
CVac
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT01617629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01617629.